WO2015188046A1 - Omega-3 compositions, dosage forms, and methods of use - Google Patents

Omega-3 compositions, dosage forms, and methods of use Download PDF

Info

Publication number
WO2015188046A1
WO2015188046A1 PCT/US2015/034372 US2015034372W WO2015188046A1 WO 2015188046 A1 WO2015188046 A1 WO 2015188046A1 US 2015034372 W US2015034372 W US 2015034372W WO 2015188046 A1 WO2015188046 A1 WO 2015188046A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
composition
fatty acids
dha
epa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/034372
Other languages
English (en)
French (fr)
Inventor
Olav SANDNES
Bruce A. Miller
Jorn DYERBERG
Steen Stender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marine Ingredients LLC
Original Assignee
Marine Ingredients LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2016015791A priority Critical patent/MX2016015791A/es
Priority to EP21157298.7A priority patent/EP3906920A1/en
Priority to MYPI2016704514A priority patent/MY186566A/en
Priority to KR1020167034160A priority patent/KR102400958B1/ko
Priority to RU2016149416A priority patent/RU2741965C2/ru
Priority to CA2950344A priority patent/CA2950344C/en
Priority to BR112016028561A priority patent/BR112016028561A8/pt
Priority to JP2016569985A priority patent/JP6755186B2/ja
Priority to EP15803689.7A priority patent/EP3151826A4/en
Application filed by Marine Ingredients LLC filed Critical Marine Ingredients LLC
Priority to CN201580030195.7A priority patent/CN106687113B/zh
Priority to AU2015269307A priority patent/AU2015269307C1/en
Publication of WO2015188046A1 publication Critical patent/WO2015188046A1/en
Priority to US15/146,680 priority patent/US9675575B2/en
Anticipated expiration legal-status Critical
Priority to US15/600,124 priority patent/US10034849B2/en
Priority to US16/023,904 priority patent/US10172819B2/en
Priority to US16/240,534 priority patent/US11160777B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • FIG. 15 is a box-and-whisker plot of the change in heart rate observed over the course of the study disclosed in Example 1.
  • FIG. 18 is a bar graph depicting mean high-density lipoprotein-cholesterol concentration at the beginning and at the conclusion of the study disclosed in Example 1.
  • FIG. 22 is a bar graph depicting mean apolipoprotein B concentrations for each arm of the study disclosed in Example 1.
  • At least about 55% of the fatty acids are omega-3 PUFAs.
  • the present disclosure encompasses a method of reducing non-high- density-lipoprotein cholesterol (non-HDL-c) in a subject comprising administering a composition or dosage form disclosed herein.
  • compositions or dosage forms may not be processed by the methods described above, but by alternative processes known in the art. Also, some compositions or dosage forms may be processed by blending already-purified oils.
  • FIGS. 1–3 provide graphical depictions of data related to changes in triglyceride levels in each arm of the study. More particularly, FIG. 1 provides a box- and-whisker plot depicting, within each group, changes in blood serum triglyceride levels between baseline levels measured at the beginning of the study and blood serum triglyceride levels measured at the conclusion of the study.
  • the box-and- whisker plot shows the median, upper and lower quartile, and maximum and minimum values (excluding outliers). Outlier data are depicted with circles or asterisks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/US2015/034372 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use Ceased WO2015188046A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP15803689.7A EP3151826A4 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use
MYPI2016704514A MY186566A (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use
CN201580030195.7A CN106687113B (zh) 2014-06-06 2015-06-05 ω-3组合物、剂型及使用方法
RU2016149416A RU2741965C2 (ru) 2014-06-06 2015-06-05 Композиции c омега-3, лекарственные формы и способы их применения
CA2950344A CA2950344C (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use
BR112016028561A BR112016028561A8 (pt) 2014-06-06 2015-06-05 composição e forma de dosagem compreendendo um óleo marinho que compreende ácidos graxos, e, uso das mesmas
JP2016569985A JP6755186B2 (ja) 2014-06-06 2015-06-05 ω−３組成物、剤形および使用法
MX2016015791A MX2016015791A (es) 2014-06-06 2015-06-05 Composiciones de omega-3, formas de dosis, y metodos de uso.
KR1020167034160A KR102400958B1 (ko) 2014-06-06 2015-06-05 오메가-3 조성물, 제형 및 사용 방법
EP21157298.7A EP3906920A1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use
AU2015269307A AU2015269307C1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use
US15/146,680 US9675575B2 (en) 2014-06-06 2016-05-04 Omega-3 compositions, dosage forms, and methods of use
US15/600,124 US10034849B2 (en) 2014-06-06 2017-05-19 Omega-3 compositions, dosage forms, and methods of use
US16/023,904 US10172819B2 (en) 2014-06-06 2018-06-29 Omega-3 compositions, dosage forms, and methods of use
US16/240,534 US11160777B2 (en) 2014-06-06 2019-01-04 Omega-3 compositions, dosage forms, and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462009145P 2014-06-06 2014-06-06
US62/009,145 2014-06-06
US201462019289P 2014-06-30 2014-06-30
US62/019,289 2014-06-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/146,680 Continuation US9675575B2 (en) 2014-06-06 2016-05-04 Omega-3 compositions, dosage forms, and methods of use

Publications (1)

Publication Number Publication Date
WO2015188046A1 true WO2015188046A1 (en) 2015-12-10

Family

ID=54767418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/034372 Ceased WO2015188046A1 (en) 2014-06-06 2015-06-05 Omega-3 compositions, dosage forms, and methods of use

Country Status (14)

Country Link
US (4) US9675575B2 (enExample)
EP (2) EP3906920A1 (enExample)
JP (2) JP6755186B2 (enExample)
KR (1) KR102400958B1 (enExample)
CN (1) CN106687113B (enExample)
AU (1) AU2015269307C1 (enExample)
BR (1) BR112016028561A8 (enExample)
CA (1) CA2950344C (enExample)
CL (1) CL2016003131A1 (enExample)
MX (1) MX2016015791A (enExample)
MY (1) MY186566A (enExample)
RU (1) RU2741965C2 (enExample)
TW (1) TWI725937B (enExample)
WO (1) WO2015188046A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021105267A1 (fr) 2019-11-26 2021-06-03 Polaris Composition d'huile de micro-organismes enrichie en acides gras polyinsatures

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
CN106687113B (zh) * 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法
CN110958731A (zh) 2018-09-21 2020-04-03 鸿盛国际有限公司 发光二极管并联电路
FR3151183A1 (fr) 2023-07-20 2025-01-24 Microphyt Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100236137A1 (en) * 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae
US7824727B2 (en) * 2001-04-06 2010-11-02 Burnbrae Farms Limited Method of making a liquid egg composition with fish oil

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
JP2000501131A (ja) * 1995-11-24 2000-02-02 ロダース・クロックラーン・ビー・ブイ 魚油をベースとする組成物
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
SE0303513D0 (sv) 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
US20070020340A1 (en) * 2005-07-25 2007-01-25 David Rubin Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension
US20090182050A1 (en) 2005-10-07 2009-07-16 Ocean Nutrition Canada, Ltd. Salts of Fatty Acids and Methods of Making and Using thereof
CA2634139C (en) 2005-12-20 2015-06-23 Cenestra, Llc. Omega 3 fatty acid formulations
US9265745B2 (en) 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
CA2655769A1 (en) 2006-06-23 2007-12-27 The Procter & Gamble Company Concentrated omega-3 fatty acids and mixtures containing them
WO2008036353A2 (en) 2006-09-19 2008-03-27 The Trustees Of Columbia University In The City Of New York Omega-3 diglyceride emulsions
EP2147088A4 (en) * 2007-04-26 2010-05-05 Patrick Adlercreutz FERTILIZED MILK OILS COMPRISING MULTIPLE-UNSATURATED FATTY ACIDS, COMPRISING EICOSAPENTAIC ACID (EPA) AND DOCOSAHEXAIC ACID (DHA), AND MANUFACTURING METHOD THEREFOR
US20100119600A1 (en) 2007-06-01 2010-05-13 Joar Opheim Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof
CL2008002020A1 (es) 2007-07-12 2008-11-14 Ocean Nutrition Canada Ltd Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite.
WO2009017102A1 (ja) * 2007-07-30 2009-02-05 Nippon Suisan Kaisha, Ltd. Epa濃縮油およびdha濃縮油の製造方法
KR101045397B1 (ko) 2008-07-04 2011-06-30 주식회사동우산업 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법
GB0813599D0 (en) 2008-07-24 2008-09-03 Pharma Marine As Method
RS53694B1 (sr) * 2008-08-07 2015-04-30 Spa Societa' Prodotti Antibiotici S.P.A. Dugoročno lečenje simptomatske srčane insuficijencije
AU2010222648B2 (en) * 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
CN101695487B (zh) * 2009-09-22 2012-01-18 北京百慧生化制药有限责任公司 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂
FR2955459B1 (fr) 2010-01-28 2013-11-22 Polaris Composition huileuse riche en monoglycerides de dha
US20110223246A1 (en) * 2010-03-10 2011-09-15 Joar Opheim Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source
WO2011133841A2 (en) 2010-04-23 2011-10-27 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Intravenous omega-3 fatty acid compositions & method of use
KR101904392B1 (ko) * 2010-09-24 2018-10-05 프로노바 바이오파마 너지 에이에스 오메가-3 지방산을 농축하기 위한 공정
US20120252888A1 (en) * 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
AU2012347606A1 (en) * 2011-12-08 2014-06-26 Metaproteomics, Llc Supplemented oil compositions and methods for improved health
WO2013093630A2 (en) * 2011-12-22 2013-06-27 Pronova Biopharma Norge As Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
EP3756658A1 (en) 2012-09-24 2020-12-30 Aker Biomarine Antarctic As Omega -3 compositions
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
CN106687113B (zh) * 2014-06-06 2021-09-03 海洋原料公司 ω-3组合物、剂型及使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7824727B2 (en) * 2001-04-06 2010-11-02 Burnbrae Farms Limited Method of making a liquid egg composition with fish oil
US20100236137A1 (en) * 2008-09-23 2010-09-23 LiveFuels, Inc. Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DYERBERG ET AL.: "Bioavailability of Marine n-3 Fatty Acid Formulations", PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 83, 2010, pages 137 - 141, XP027271472 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021105267A1 (fr) 2019-11-26 2021-06-03 Polaris Composition d'huile de micro-organismes enrichie en acides gras polyinsatures

Also Published As

Publication number Publication date
AU2015269307A1 (en) 2017-01-05
RU2016149416A (ru) 2018-07-10
BR112016028561A2 (pt) 2017-08-22
RU2741965C2 (ru) 2021-02-01
US20210308086A1 (en) 2021-10-07
AU2015269307C1 (en) 2019-10-03
RU2016149416A3 (enExample) 2018-12-05
US20160243068A1 (en) 2016-08-25
KR20170018825A (ko) 2017-02-20
US9675575B2 (en) 2017-06-13
CA2950344A1 (en) 2015-12-10
US20180303784A1 (en) 2018-10-25
AU2015269307B2 (en) 2019-03-14
TW201613571A (en) 2016-04-16
EP3151826A4 (en) 2018-01-24
US11160777B2 (en) 2021-11-02
JP6755186B2 (ja) 2020-09-16
CN106687113A (zh) 2017-05-17
CA2950344C (en) 2023-09-19
EP3151826A1 (en) 2017-04-12
EP3906920A1 (en) 2021-11-10
US20170252313A1 (en) 2017-09-07
MY186566A (en) 2021-07-27
US10172819B2 (en) 2019-01-08
BR112016028561A8 (pt) 2021-06-29
TWI725937B (zh) 2021-05-01
US10034849B2 (en) 2018-07-31
JP2020105224A (ja) 2020-07-09
KR102400958B1 (ko) 2022-05-20
CL2016003131A1 (es) 2017-06-09
CN106687113B (zh) 2021-09-03
JP2017516811A (ja) 2017-06-22
MX2016015791A (es) 2017-05-30

Similar Documents

Publication Publication Date Title
US11160777B2 (en) Omega-3 compositions, dosage forms, and methods of use
Calviello et al. Low-dose eicosapentaenoic or docosahexaenoic acid administration modifies fatty acid composition and does not affect susceptibility to oxidative stress in rat erythrocytes and tissues
CN103221524B (zh) 用于浓缩omega-3脂肪酸的方法
JP6953504B2 (ja) エイコサペンタエン酸アルキルエステルを含有する組成物及びその製造方法
EP3428255B2 (en) Method for producing refined palm-based fat/oil, and method for reducing glycidol, 3-chloropropane-1,2-diol and fatty acid esters thereof and/or diglycerides in refined palm-based fat/oil
Guerra et al. Plasma phospholipidomic profile differs between children with phenylketonuria and healthy children
WO2016113922A1 (ja) 育児用調製粉乳に用いるための油脂組成物
JP2021155756A (ja) 水産物由来遊離１価不飽和脂肪酸又はその低級アルコールエステルの製造方法
CN108541775A (zh) 一种亚麻籽油与火麻籽油调和食用油及其制备方法
JP6763521B2 (ja) ２−ｄｈａ−リゾホスファチジルコリン含有脂質組成物及びその製造方法
EP2464240A1 (en) Phytanic acid fractionation process, fatty acid products and use thereof
JP4904751B2 (ja) 生体内ｄｈａ合成促進剤
Radcliffe et al. Effect of dietary fish oil on tumor‐induced hyperlipidemia and tumor growth in rats implanted with a methylcholanthrene‐induced sarcoma
JP3550176B2 (ja) トコフェロール強化精製エゴマ油、それを含有する脂肪輸液剤及び経口投与製剤
JP6903846B2 (ja) 組成物
HYPERLIPIDEMIA EFFECT OF DIETARY FISH OIL ON
UA124828U (uk) Купажована рослинна олія

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15803689

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2950344

Country of ref document: CA

Ref document number: 2016569985

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/015791

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20167034160

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015803689

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016028561

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2015803689

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015269307

Country of ref document: AU

Date of ref document: 20150605

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016149416

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112016028561

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20161205